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Abstract
Background: Aberrant epigenetic silencing plays a major role in cancer formation by inactivating tumor suppressor genes.
While the endpoints of aberrant silencing are known, i.e., promoter region DNA methylation and altered histone
modifications, the triggers of silencing are not known. We used the tet-off system to test the hypothesis that a transient
reduction in gene expression will sensitize a promoter to undergo epigenetic silencing.
Methodology/Principal Findings: The tet responsive promoter (PTRE) was used to drive expression of the selectable human
HPRT cDNA in independent transfectants of an Hprt deficient mouse cell line. In this system, high basal HPRT expression is
greatly reduced when doxycycline (Dox) is added to the culture medium. Exposure of the PTRE-HPRT transfectants to Dox
induced HPRT deficient clones in a time dependent manner. A molecular analysis demonstrated promoter region DNA
methylation, loss of histone modifications associated with expression (i.e., H3 lysine 9 and 14 acetylation and lysine 4
methylation), and acquisition of the repressive histone modification H3 lysine 9 methylation. These changes, which are
consistent with aberrant epigenetic silencing, were not present in the Dox-treated cultures, with the exception of reduced
H3 lysine 14 acetylation. Silenced alleles readily reactivated spontaneously or after treatment of cells with inhibitors of
histone deacetylation and/or DNA methylation, but re-silencing of reactivated alleles did not require a new round of Dox
exposure. Inhibition of histone deacetylation inhibited both the induction of silencing and re-silencing, whereas inhibition
of DNA methylation had no such effect.
Conclusions/Significance: This study demonstrates that a transient reduction in gene expression triggers a pathway for
aberrant silencing in mammalian cells and identifies histone deacetylation as a critical early step in this process. DNA
methylation, in contrast, is a secondary step in the silencing pathway under study. A model to explain these observations is
offered.
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Introduction
Aberrant epigenetic silencing is a common and significant
mechanism in cancer development and progression [1]. Like
mutational events, aberrant silencing frequently inactivates tumor
suppressor genes in both sporadic tumors and human cancer cell
lines [2]. Unlike mutations, however, silencing is a stepwise process
[3,4] with potential for reversal [5]. These observations have led to
research to identify the molecular changes that accompany
silencing. Such changes include promoter region DNA methyla-
tion, histone deacetylation, histone methylation at specific residues
(e.g. H3K9, H3K27), and densely packed nucleosomes that create
a closed chromatin structure [6]. However, a caveat is that these
changes are most often documented at stably silenced alleles that
were under continuous selective pressure within the tumor
microenvironment for maintenance of the silenced state. There-
fore, reported epigenetic modifications represent an ultimate
endpoint and do not reveal how silencing initiates, nor do they
reveal the order of epigenetic modifications that occur during the
transition from active expression to stable silencing. Such
information is required to create strategies to prevent the initiation
or progression of aberrant epigenetic silencing.
Many models designed to examine initiation of silencing track
normal epigenetic changes during development at imprinted genes
[7] or during X chromosome inactivation [8], but developmentally
programmed silencing may progress differently than aberrant
silencing occurring in cancer. Promoter DNA methylation is the
most common modification associated with epigenetic silencing,
and has previously been thought to play a causal role [9], but
evidence is accumulating to suggest DNA methylation as a late
step in the silencing process. For example, DNA methylation
occurs after histone modifications for silenced, stably integrated
transgenes [10]. A similar progression of epigenetic modifications
occurs for silencing of the endogenous tumor suppressor gene
RASSF1A [11]. Previous studies in our laboratory showed that
silencing of an integrated Aprt transgene allows the spread of DNA
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transcriptional state [4]. Although DNA methylation has been the
most common modification associated with cancer-related silenc-
ing, examples of epigenetic silencing occurring independent of
DNA methylation show it is not an absolute requirement [12–14].
Collectively these data suggest that DNA methylation primarily
functions to maintain and stabilize the silenced state and that other
epigenetic processes are required to initiate silencing.
If DNA methylation is neither a required nor an initiating step
for aberrant silencing, how is this process triggered? Recent studies
suggest reduced expression as one possibility. For example, in
ovarian cancer loss of the GATA6 transcription factor results in
reduced expression and subsequent epigenetic silencing of the
downstream target Disabled-2 [15]. Also, inhibition of ERa
(estrogen receptor a) signaling in breast cancer cell lines reduces
expression and induces silencing of the downstream target gene,
PR (progesterone receptor) [16]. These are two instances that
involve loss of transcriptional activators, but evidence also exists
that reducing expression by inappropriate recruitment of tran-
scriptional repressors can lead to silencing. An inherited mutation
in the DAPK1 promoter apparently causes B-cell chronic
lymphocytic leukemia by increased localization of a transcriptional
repressor that reduces expression and correlates with silencing
[17]. In addition to altered signaling pathways, some environ-
mental changes accompanying tumor progression also reduce gene
expression, which could initiate silencing. For example, hypoxia. a
common feature of tumor microenvironments, represses expres-
sion of tumor suppressor genes (e.g., E-CAD, BRCA1, MLH1, and
RUNX) [18–21] frequently silenced in cancer [2,22,23].
In the current study we have developed a system to directly test
the hypothesis that a transient reduction in gene expression can
sensitize a promoter to undergo epigenetic silencing. The results
demonstrate that this principle is correct. Additionally, we find
that induction of silencing is dependent on histone deacetylase
activity, but does not require DNA methylation.
Results
A system to study transient reductions in gene
expression
Totestthehypothesisthatatransientreductioningeneexpression
can initiate epigenetic silencing, we used the tet-off system [24] to
controltranscriptionlevelsofhumanHPRTcDNAinthemouseDif-
6 cell line, which lacks expression of endogenous Hprt [25]. In this
system the tet-Transcriptional Activator (tTA) localizes to the tet-
responsivepromoter(PTRE)andpromotesHPRTexpression(Fig.1A).
Adding the tetracycline analog doxycycline (Dox) to the growth
medium reduces HPRT expression by directly binding tTA and in-
hibiting its localization to the promoter (Fig. 1B). Three stable trans-
fectants, HP11, HP13, and HP14, expressing high levels of HPRT
were established. After 48 hours growth in Dox medium, HPRT
expression was reduced by more than 90% relative to untreated
controls,withtheHP11celllineexhibitingthestrongestDoxresponse
(Fig. 1C). Although HPRT expression is significantly reduced, cell
cultures growing in Dox media remain sensitive to selection against
HPRT (Fig. S1) and can grow under conditions that require HPRT
expression(datanotshown).Aconcentrationof1 mg/mlDoxshowed
a maximum effect on expression without causing toxicity (data not
shown) and was used in all subsequent Dox treatments.
A transient reduction in gene expression induces
phenotypic gene inactivation
Following removal of Dox from the culture medium the tTA
protein can again bind to PTRE and restore HPRT expression.
However, our hypothesis predicts that during the period of
reduced expression a fraction of alleles will become epigenetically
silenced and thus will be unable to restore HPRT expression upon
removal of Dox. To test this hypothesis, cells were grown in Dox
media for a week to reduce expression and allow adequate time for
HPRT protein turnover before removing Dox and selecting for
HPRT deficient cells with the purine analog 6-thioguanine (TG).
The fraction of surviving TG-resistant cells reflects the gene
inactivation frequency for PTRE-HPRT. Dox exposure was found
to induce TG-resistant cells for all three cell lines, at frequencies
ranging from 1.4610
23 to 9.4610
22, which were several orders of
magnitude higher than untreated cultures (Fig. 2A). Moreover,
Figure 1. Treatment with doxycycline (Dox) reduces PTRE-HPRT
expression. (A) The tet-off system was used to express HPRT. The
1.38 kb HPRT cDNA was cloned into the 59 EcoR I and 39 Xba I restriction
sites downstream of the minimal CMV promoter (PminCMV). In the
absence of Dox, tTA binds to the seven 19 bp tet operator (tetO)
sequence repeats in the promoter and activates high expression of
HPRT. (B) Adding Dox reduces HPRT expression by direct binding of tTA,
though minimal expression levels remain. (C) HPRT mRNA levels are
significantly reduced within 48 hours of growth in media containing
1 mg/ml Dox. HPRT expression was measured by quantitative RT-PCR
(qRT-PCR) and normalized to Gapdh expression levels. Each bar
represents the average of triplicate reactions with error bars indicating
minimum and maximum fold change.
doi:10.1371/journal.pone.0004832.g001
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tions of initial Dox exposure (Fig. 2B). These results demonstrate
that transient reductions in gene expression correlate with greatly
increased frequencies of PTRE-HPRT inactivation.
Epigenetic modifications consistent with silencing
characterize inactivated PTRE-HPRT alleles
Individual TG-resistant clones were characterized to identify
molecular changes correlating with PTRE-HPRT inactivation. TG-
resistant clones were isolated from the HP13 and HP14 parental
lines following one week of Dox treatment. HPRT mRNA levels in
all TG-resistant clones were substantially lower than those
observed in the Dox treated parental cells (Fig. 3). DNA
methylation at the PTRE-HPRT promoters of HP14-derived TG-
resistant cells was measured via bisulfite sequencing (Fig. 4). As
expected, all CpG sites within the PCMVmin, tetO repeats, and
nearby regions were unmethylated in actively expressing HP14
cells. Moreover, these sites remained unmethylated in the same
cells grown in the presence of Dox for one week. In contrast, all
TG-resistant clones analyzed exhibited DNA methylation in the
promoter region, though the density of DNA methylation varied
(Fig. 4). TG1 and TG2 both exhibited low levels of DNA
methylation and contained some alleles without any methylated
CpG sites in the minimal CMV promoter (PminCMV). In contrast,
TG5 and TG6 exhibited substantially more DNA methylation
within the promoter, including the core PminCMV region. The other
two TG-resistant lines, TG3 and TG4, contained intermediate to
high levels of DNA methylation within the promoter relative to the
other cell lines (Fig. S2).
The absence of dense promoter DNA methylation in some
clones suggested additional mechanisms were contributing to
PTRE-HPRT inactivation. Chromatin immunoprecipitation (ChIP)
analysis was used to measure specific histone modifications
associated with either active transcription (methyl-K4, acetyl-K9,
and acetyl-K14 of histone H3) or silenced transcription (dimethyl-
K9 of histone H3) at the PTRE-HPRT promoter (Fig. 5). As
expected, cells expressing high levels of HPRT have a histone
modification pattern at the promoter consistent with active
transcription. Specifically, the actively transcribed PTRE–HPRT
promoter was associated with high levels of H3 acetylation
(Fig. 5A) and methylation at lysine 4 (methyl-K4 H3) (Fig. 5B)
relative to modification levels measured at the active Gapdh
promoter (P-Gapdh). The repressive modification dimethyl-K9 H3
was low in the HPRT expressing cells (Fig. 5C), measured relative
to the silenced Mage-a locus (P-Mage) [26,27]. Reducing HPRT
expression by treating cells with Dox did not reduce levels of
methyl-K4 H3 (Fig. 5B) or significantly change the levels of
dimethyl-K9 H3 (Fig. 5C) at the PTRE-HPRT promoter. However,
H3 acetylation decreased significantly after reducing HPRT
expression by Dox treatment (Fig. 5A). The antibody used for
Figure 2. Dox exposure induces PTRE-HPRT inactivation. (A)
Reducing expression of PTRE-HPRT by growing cells for 1 week in
medium containing 1 mg/ml Dox increased the frequency of gene
inactivation, as measured by TG-resistance. TG-resistance was measured
by washing out Dox, selecting cells with 5 mg/ml TG, and counting
surviving colonies after 2 weeks of continuous selection. During Dox
treatment or the equivalent period without treatment, cells were
maintained in medium containing puromycin and G418 to maintain the
PTRE-HPRT and tTA constructs respectively, but without azaserine/
hypoxanthine (AzHx) selection. Only cells that express HPRT can grow in
AzHx selection. (B) TG-resistance frequencies increased as a function of
time HP13 cells were exposed to Dox before starting TG selection. HP13
cells were continuously cultured in 1 mg/ml Dox for 3 weeks, and TG-
resistance was measured at different points during the Dox treatment
(3, 5, 7, 14, and 21 days). A parallel control culture was maintained in
medium containing puromycin and G418 without Dox, and TG-
resistance was measured after 21 days (Untreated).
doi:10.1371/journal.pone.0004832.g002
Figure 3. PTRE-HPRT inactivation correlates with reduced mRNA
levels. Dox-induced TG-resistant clones were isolated and expanded.
HPRT mRNA levels in TG-resistant clones from the HP13 (TG7 and TG8)
and HP14 (TG1 and TG5) parental cells are lower than both active
expression levels (Untreated) and reduced expression levels after
exposure to Dox for one week (Dox). HPRT mRNA was measured by
qRT-PCR and normalized to Gapdh expression levels. Each bar
represents the average of triplicate reactions with error bars indicating
minimum and maximum fold change.
doi:10.1371/journal.pone.0004832.g003
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H3 [28]. To probe this decrease further, an additional ChIP was
conducted with antibody directed specifically against acetyl-K9
H3. In this case, no decrease was observed after the one-week
exposure to Dox (Fig. 5D). Therefore, reducing expression by Dox
treatment caused loss of acetyl-K14 H3 without decreasing other
modifications associated with transcriptional activity, i.e., methyl-
K4 H3 or acetyl-K9 H3. Dox treatment had no effect on histone
modifications measured at the control promoters (P-Gapdh and P-
Mage) used for normalization.
In contrast to the observations for histone modifications in the
presence of Dox, ChIP analysis for the Dox-independent, TG
resistant clones revealed markedly reduced levels of methyl-K4 H3
and acetyl-K9 H3. Increased dimethyl-K9 H3 was also observed
at the PTRE-HPRT promoter in the TG-resistant cells, ranging
from a 2-fold increase in TG6 to a nearly 5-fold increase in TG5
(Fig. 5C). These results demonstrate that the transition from
reduced expression to gene inactivation is associated with a shift
from activating to repressive histone modifications consistent with
epigenetic silencing.
Silenced PTRE-HPRT alleles are reactivated by inhibiting
histone deacetylases or DNA methylation
One of the hallmarks of epigenetic silencing is reversibility. To
confirm definitively that the induced PTRE–HPRT inactivation was
due to silencing, we measured the effects of inhibiting histone
deacetylation and/or DNA methylation on gene reactivation in
the TG-resistant cells. First, changes in HPRT mRNA levels were
measured for the TG-resistant cells after inhibiting histone
deacetylation with trichostatin A (TSA) treatment or inhibiting
DNA methylation with 5-aza-29-deoxycytidine (5-aza-dC) (Fig. 6A
and Fig. S3). The different TG-resistant clones had varied
responses to histone deacetylase (HDAC) inhibition ranging from
an approximately 3-fold increase in HPRT mRNA (TG1 and
TG2) to no response (TG5). Inhibiting DNA methylation gave a
nearly reciprocal result with the TG5 cell line showing the largest
5-aza-dC induction of HPRT mRNA, an approximately 5-fold
increase, and little response in the TG1 and TG2 clones, which
exhibited the strongest response after HDAC inhibition. Combin-
ing inhibition of histone deacetylases and DNA methylation by
treating the cells with 5-aza-dC and TSA simultaneously resulted
in synergistic induction of HPRT expression for every TG-resistant
cell lines except for TG5, which exhibited at best an additive effect
(Fig. 6A and Fig. S3).
Next we determined if the silenced alleles could phenotypically
reactivate by selecting for revertant cells in media requiring HPRT
expression for survival (azaserine / hypoxanthine or AzHx). Two
TG-resistant cell lines, TG1and TG5, spontaneously gave rise to
AzHx-resistant colonies at frequencies of 9.3610
23 and
8.2610
24, respectively (Fig. 6B). TSA and 5-aza-dC treatments
were used to determine if inhibiting histone deacetylases or DNA
methylation, respectively, would induce phenotypic reactivants
similar to their effects on induced reactivation at the RNA level
(Fig. 6B and Fig. S3). Phenotypic reactivants were induced, though
the results did not mimic precisely those obtained by measuring
HPRT mRNA levels. For example, TSA treatment increased the
frequency of phenotypic reactivation of the TG5 cell line despite
the apparent lack of induction when measuring HPRT mRNA one
day after TSA treatment. While these discrepancies reveal
differences between the two assays, the combined results clearly
demonstrate that TG-resistance was due to epigenetic mecha-
nisms.
Reactivated alleles exhibit memory of transcriptional
silencing
Several laboratories have reported that 5-aza-dC reactivated
promoters exhibit rapid re-silencing [29,30]; however these
experiments could not use selection to maintain expression. Our
system allowed continuous selection to ensure maintenance of the
reactivated promoter state by growing the cells in AzHx medium,
which requires HPRT enzyme activity for cell survival. We
therefore asked whether promoter reactivation stabilized under
selective conditions or alternatively whether the reactivated
promoters retained a memory of silencing, as defined by high
frequency re-silencing. Although selection ensures HPRT expres-
sion, the absolute expression levels were variable ranging from
14% to 90% of HPRT expression in the parental cells (Fig. S4).
Two clones, reactivants 1 and 2, were isolated from TG-resistant
HP13 cells that had spontaneously reactivated HPRT expression
and grew well in AzHx medium. Spontaneous and Dox-induced
silencing frequencies were determined for both clones (Fig. 7A).
Figure 4. PTRE-HPRT inactivation correlates with increased
promoter DNA methylation. Allelic methylation patterns for
parental HP14 cells expressing high levels of HPRT (Untreated), reduced
levels of HPRT after an 1 week Dox treatment (Dox), and HP14-derived
TG-resistant clones (TG1, TG2, TG5, and TG6). Bisulfite sequencing
identified methylated (closed triangles) and unmethylated (open
triangles) CpG sites within individual alleles. Schematic of the promoter
shows approximate positioning of CpG sites (vertical bars) within the
minimal CMV promoter (green shaded box) and the 59 region (,42 bp)
of the HPRT cDNA sequence (grey shaded box). The start of the HPRT
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frequencies, 1.8610
22 and 6.8610
23, relative to the initial HP13
silencing frequency of 4.5610
26, with Dox treatment only
inducing an approximately 3-fold increase in silencing frequencies.
Three reactivant clones from the HP14 TG1 cell line
(reactivants 4–6) were examined and also showed that Dox
treatment was not required for high frequency PTRE-HPRT re-
silencing (Fig. 7B). The spontaneous silencing frequency for
parental HP14 cells was less than 6610
26 (Fig. 2A), but all
reactivant cell lines had spontaneous silencing frequencies (10
23 to
10
22) equal to or higher than that induced by the week-long Dox
treatment (,10
23). Knowing that the silenced state was reversible
by inhibiting DNA methylation or histone deacetylation, we
examined whether either of these events were required for re-
silencing. After inhibiting DNA methylation with 5-aza-dC, the re-
silencing frequencies were essentially unchanged relative to the
high spontaneous frequencies. In contrast, HDAC inhibition
by treatment with TSA reduced the re-silencing frequencies
from 5- to 20-fold. In total, these results showed that the
reactivated cells no longer required a period of Dox-mediated
transcriptional reduction to silence expression and suggested that
re-silencing was dependent on histone deacetylation, but not DNA
methylation.
Initiation of silencing is dependent on histone
deacetylase activity but not DNA methylation
After demonstrating that HDAC inhibition reduced re-silencing
of reactivated alleles, we tested whether inhibiting HDACs or
DNA methylation would affect initial silencing induced by Dox
treatment. Induced silencing frequencies were measured again for
the HP13 and HP14 parental HPRT expressing cell lines, with the
modification of adding TSA or 5-aza-dC for the last 16 hours the
cells were in Dox media. Inhibiting DNA methylation did not
significantly affect the Dox-induced silencing frequency, but
HDAC inhibition drastically reduced the silencing frequency
(Fig. 8). These results show that HDAC activity is an early
requirement for silencing induced by decreased transcription in
our model, but DNA methylation is not required.
Discussion
Aberrant epigenetic silencing is a significant mechanism of
tumor suppressor gene inactivation, but how this process initiates
in mammalian cells is poorly understood. We used the tet-off
system to test the hypothesis that a transient and reversible
reduction in gene expression could sensitize a promoter to
undergo silencing. This hypothesis was based on observations
Figure 5. PTRE-HPRT inactivation correlates with repressive histone modifications. ChIP analysis measuring histone H3 modifications at the
PTRE-HPRT promoter in HP14 cells expressing high levels of HPRT (Untreated), reduced levels of HPRT after 1 week Dox treatment (Dox), and HP14-
derived TG-resistant cell lines (TG1, TG5, and TG6). (A) ChIP analysis measuring acetylated histone H3 using a polyclonal antibody raised against a
peptide corresponding to acetyl-K9 and acetyl-K14. (B) ChIP analysis measuring methylation at lysine 4 of histone H3 (methyl-K4 H3). The antibody
used for immunoprecipitation recognizes all three forms of methylation at K4, mono-, di-, and tri-methyl. (C) ChIP analysis measuring the repressive
modification of dimethylation at lysine 9 of histone H3 (di-methyl-K9 H3). (D) ChIP analysis measuring acetylation at lysine 9 of histone H3 (acetyl-K9
H3). Immunoprecipitated DNA levels were quantified by qRT-PCR. Specific signal was calculated by measuring fold change between pull down and
input at the Hprt promoter (PTRE-HPRT), Gapdh promoter (P-Gapdh), and Mage-a promoter (P-Mage-a). For activating modifications, levels at PTRE-HPRT
are displayed relative to the Gapdh promoter; for the repressive modification, dimethyl-K9 H3, results are displayed relative to the Mage promoter.
Error bars indicate the SD from triplicate reactions.
doi:10.1371/journal.pone.0004832.g005
Induced Aberrant Silencing
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tumor suppressor gene silencing (see Introduction) and results
from our laboratory showing transcriptional silencing allowed
DNA methylation to spread into a promoter region [4]. Moreover,
some tumor suppressor genes that are frequently silenced in cancer
are also repressed by specific environmental exposures. For
example, the tumor microenvironment causes hypoxia, which
represses the E-Cadherin [18], BRCA1 [19], and MLH1 [20] tumor
suppressor genes. All are epigenetically silenced in one or more
cancer types [2], which suggests a relation between transcriptional
repression and silencing in cancer. Here we report results from an
experimental system that allowed us to demonstrate that a
reduction in gene expression can trigger epigenetic silencing.
Dox treatment reduces expression in the tet-off system by
preventing association of the tTA activator protein with the
promoter, but reduced expression is not equivalent to epigenetic
silencing. For example, the Dox-treated cultures remained
sensitive to TG while silenced clones are TG-resistant (Fig. S1).
However, a small fraction of cells exposed to Dox exhibited HPRT
levels that are reduced further, which provided TG-resistance, and
the fraction of cells increases with longer durations of Dox
exposure. The induced TG-resistance was also relatively stable
because it did not require continued exposure to Dox. These
observations demonstrate that the reduced expression in the
presence of Dox sensitized some alleles to undergo epigenetic
silencing, but was insufficient to confer TG-resistance by itself. All
evidence obtained in these experiments supported the conclusion
that Dox-induced TG-resistance was due to epigenetic silencing as
opposed to mutational events. The best evidence was the ability of
TG-resistant cells to reactivate expression and restore functional
HPRT activity, which was evident by growth of the cells in AzHx
media. Besides the nine different TG-resistant clones described in
this paper, we examined an additional fifteen TG-resistant clones
Figure 6. Silenced PTRE-HPRT alleles are reactivated by inhibit-
ing histone deacetylation or DNA methylation. (A) Inhibition of
DNA methylation and histone deacetylation increased HPRT mRNA
levels. HP14-derived TG-resistant cell lines (TG1, TG2, TG5, and TG6)
were treated with 300 nM 5-aza-dC (Aza-dC), inhibiting histone
deacetylation with 100 nM trichostatin A (TSA), or a combination of
the 300 nM 5-aza-dC and 100 nM TSA treatments (Aza-dC+TSA). Cells
were treated with inhibitors overnight (,16 hours), and RNA was
harvested 24 hours later. The units shown along the Y-axis are relative
to those measured in the untreated parental HP14 cells (see Figure 3).
HPRT expression was measured by qRT-PCR and normalized to Gapdh
expression levels. Each bar represents the average of duplicate
reactions with error bars indicating minimum and maximum fold
change. (B) TG-resistant cell lines were capable of reactivating PTRE-
HPRT expression. Cells were plated with azaserine/hypoxanthine (AzHx)
selection, which requires HPRT enzyme activity for cell survival, to
isolate and measure the number of cells that reactivated HPRT
expression. Before plating and selection, cells were treated overnight
with 300 nM 5-aza-dC (Aza-dC), 100 nM TSA (TSA), or vehicle control
(untreated) and allowed to recover for 24 hours. Frequencies represent
the fraction of cell colonies surviving after two weeks of continuous
AzHx selection.
doi:10.1371/journal.pone.0004832.g006
Figure 7. Reactivation of silenced PTRE-HPRT alleles is unstable.
(A) PTRE-HPRT inactivation frequencies for HP13-derived clones with
epigenetically silenced and then reactivated HPRT expression (Reacti-
vant 1 and 2) were measured after one week without Dox exposure
(Untreated) or after one week Dox treatment (Dox). The silencing
frequency for the parental HP13 cell line (HP13) is shown for
comparison. (B) PTRE-HPRT inactivation frequencies for HP14-derived
clones with epigenetically silenced and then reactivated HPRT
expression (Reactivants 4–6) were measured after overnight treatment
with 300 nM 5-aza-dC (Aza-dC), 100 nM TSA (TSA), or vehicle control
(Untreated) before selecting against HPRT activity with TG. Frequencies
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silencing (i.e., TSA or 5-aza-dC induction of HPRT mRNA or
reactivant cell clones) was measured in each of these TG-resistant
clones. In total, all twenty-four of the examined Dox-induced
clones were shown to have silenced PTRE-HPRT alleles. Addition-
ally, the silencing frequencies induced by Dox treatment were
orders of magnitude higher than that expected for HPRT
inactivating mutations (,10
26), and a previous study that
characterized base-pair substitutions in the Dif-6 cells showed
they do not have a mutator phenotype [31]. Dox treatment has
also been used extensively in cell culture without having displayed
mutagenic properties.
High-level promoter expression in the tet-off system occurs via
localization of the tTA protein and activity of its VP16 activation
domain; this domain promotes expression through recruitment of
TBP, TFIIB, and the SAGA complex [32]. Then reduced
expression during Dox treatment likely results from losing
recruitment of these factors. The resultant disruption in recruit-
ment of the SAGA complex and its associated histone acetyltrans-
ferases may therefore cause the concurrent decrease in acetyl-K14
H3. In contrast, acetyl-K9 H3 did not decrease when gene
expression was reduced by Dox treatment, which demonstrates
that the acetylation state of K9 and K14 of H3 may be regulated
independently. Previous studies have also observed acetylation at
K9 H3 can remain high despite decreased gene expression levels
[33]. Levels of the repressive histone modification dimethyl-K9 H3
remained relatively low during reduced expression in the presence
of Dox, which is not surprising considering the continuing
presence of acetyl-K9 H3 should prevent the addition of methyl
groups at K9 H3. Hypoxic conditions have been reported to
increase dimethyl-K9 H3 upon repression of the mouse Mlh1 [34]
and human RUNX3 promoters [21]. Increased dimethyl-K9 H3
has also been reported to result from nickel exposure [35], which
can induce silencing of a gpt transgene in hamster cells [36]. While
reduced expression alone did not induce methylation of K9 H3 in
our system, increased levels of dimethyl-K9 H3 were observed
after alleles transitioned to the silenced state identified by TG-
resistance.
Results provided by our experiments help establish specific
distinctions between the states of transcriptional repression and
epigenetic silencing. In our system epigenetic silencing was defined
as HPRT expression that was reduced to levels that allowed growth
in TG selection. Therefore, the most evident difference was that
clones with silenced alleles were TG-resistant while cells growing
in Dox remained sensitive to TG selection (Fig. S1). The molecular
basis of this phenotypic difference was demonstrated by showing
TG-resistant cells had lower levels of HPRT mRNA than cells
treated with Dox (Fig. 3) and molecular changes associated with
epigenetic silencing (Figs. 4, 5, and S2). While the reduced
expression after Dox treatment correlated with a loss of acetyl-K14
H3 at the PTRE-HPRT promoter, TG-resistance and epigenetic
silencing correlated with additional molecular changes including
DNA methylation, reduced methyl-K4 H3, loss of acetyl-K9 H3,
and increased dimethyl-K9 H3 at the PTRE-HPRT promoter.
Although increased DNA methylation was one of the molecular
changes observed at silenced promoters in our system, DNA
methylation was not required for the initiation of silencing because
5-aza-dC treatment had no effect on the frequency of silenced
clones induced by Dox treatment. Evidence that the 5-aza-dC
treatment used here was sufficient to inhibit DNA methylation was
provided with experiments showing 5-aza-dC treatment induced
reactivation of silenced PTRE-HPRT promoters that were hyper-
methylated (Fig. 6 and S3). Additionally, bisulfite sequencing
analysis showed HPRT silencing in the TG1 and TG2 cell lines did
not require high levels of DNA methylation (Fig. 4). In contrast to
inhibition of DNA methylation, inhibiting HDAC activity
prevented most, but not all, of the Dox-dependent increase in
HPRT silencing. This observation suggests the presence of two
populations of silenced alleles at the end of the Dox treatment.
One population would be silenced alleles that are readily
reactivated by TSA treatment, and the second population would
be alleles that are more stably silenced and fail to restore HPRT
expression after TSA treatment. Presumably, the second popula-
tion would have acquired additional repressive epigenetic
modifications that cooperate with histone deacetylation to stabilize
the silenced state.
A speculative model (Fig. 9) to explain the results obtained
herein is that promoters with high transcriptional activity are
resistant to silencing and are characterized by epigenetic
modifications commonly associated with active expression
(Fig. 9A). After transcriptional activity decreases at the promoter,
acetyl-K14 H3 levels are reduced, and the promoter is more
susceptible to epigenetic silencing (Fig. 9B). Although decreased
acetyl-K14 H3 alone is not sufficient to induce epigenetic
silencing, loss of this modification could decrease protection of
the promoter from epigenetic silencing. Similarly, histone H3
acetylation has been shown to establish a protective boundary
against spreading of DNA methylation [10]. The transition from
reduced expression to epigenetic silencing initiates with histone
deacetylation based on the observations that acetyl-K9 H3 levels
were low at silenced PTRE-HPRT promoters and inhibiting class I
and II HDACs reduced the frequency of epigenetic silencing
(Fig. 9C). Initially the silenced alleles are unstable and can be
reactivated by TSA treatment, but as additional epigenetic
modifications occur the silenced state stabilizes and is resistant to
TSA treatment alone (Fig. 9D). We propose DNA methylation as
a late step in epigenetic silencing because 5-aza-dC treatment did
not affect the initiation of silencing. Although loss of methyl-K4
H3 is also shown as a secondary step, our results are not
inconsistent with this loss being an early step in epigenetic silencing
similar to loss of acetyl-K9 H3. While future experiments are
required to test this model directly, aspects of it are consistent with
prior observations. One is that silencing is a multistep process in
which DNA methylation occurs downstream of silencing initiation
[4]. This conclusion is supported by multiple observations of DNA
Figure 8. Histone deacetylase inhibition prevents Dox-induced
PTRE-HPRT silencing. PTRE-HPRT inactivation frequencies for HP13 and
HP14 cells were measured after treatment exposure to 1 mg/ml Dox for
one week (Dox), exposure to Dox for one week plus 300 nM 5-aza-dC
for the last 16 hours (Aza-dC), exposure to Dox for one week plus
100 nM TSA for the last 16 hours (TSA), or no treatments (Untreated).
Frequencies represent the fraction of cell colonies surviving after two
weeks of continuous TG selection.
doi:10.1371/journal.pone.0004832.g008
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examples of DNA methylation-independent silencing [12–14].
A current focus in cancer treatment is reactivating silenced
tumor suppressor genes in malignant cells through the use of
pharmacological agents [5]. Although inhibiting DNA methylation
and histone deacetylation usually reactivates expression of silenced
alleles [38,39], such renewed expression is often unstable and
quickly re-silences at a high frequency, possibly as a consequence
of retention of some repressive histone modifications [29,30].
Although temporary reactivation of tumor suppressor genes may
be sufficient to induce anti-tumor effects, re-silencing would ensure
that these effects are short-lived. Thus, it would be helpful to know
if high frequency re-silencing reflects a lack of prolonged
expression, or alternatively if silenced and reactivated alleles have
a persistent memory of the silenced state. To distinguish these
possibilities, we isolated subclones from cells with silenced PTRE-
HPRT that spontaneously reactivated expression and used
selection for HPRT to maintain the reactivated state for at least
one month (,50 cell divisions). Despite the prolonged time of
reactivated expression, the absolute level of expression is not
always restored to the original level (Fig. S4), and the reactivated
PTRE-HPRT alleles still re-silence at a high frequency. Addition-
ally, re-silencing did not require the Dox-mediated reduction in
expression that was required for the initial silencing event. Thus,
the memory of silencing was clearly persistent and likely reflects
retention of epigenetic modifications. The inhibition of re-silencing
with TSA suggests similarities with the initiation of silencing,
which was also inhibited with TSA treatment.
We propose that the PTRE-HPRT system presented in this study
represents a valid model for initiation and progression of aberrant
silencing in cancer because silenced PTRE-HPRT alleles display the
hallmarks of tumor suppressor gene silencing (promoter region
DNA methylation, histone hypoacetylation, loss of methyl-K4 H3,
and gain of methyl-K9 H3). In other words, we believe that the
principle of reduced expression as a trigger for silencing will apply
to bona fide mammalian promoters. Although our system utilized a
non-mammalian promoter, endogenous levels of enzymes that
control histone modifications and DNA methylation were
responsible for the transition from repression to silencing. This is
a unique and significant difference between our experimental
system and previous systems that induced silencing by direct
recruitment of repressive protein domains [40] or direct
establishment of DNA methylation [41,42] at promoters. Hence,
our system has the potential to detect multiple independent
pathways of epigenetic silencing, which could be cell type specific.
For example, histone modifications and DNA methylation are
both observed at silenced promoters in colon cancer cells, whereas
some of the same promoters only exhibit histone modifications
when silenced in prostate cancer cells [14].
Figure 9. A model for induced silencing via reduced gene
expression. (A) The VP16 activation domain promotes high levels of
expression. DNA in the promoter region DNA is unmethylated and
histone H3 is enriched for activating modifications (methyl-K4, acetyl-
K9, and acetyl-K14). (B) Adding Dox reduces expression levels and
acetylation at K14 of histone H3. (C) Reduced expression sensitizes
alleles to undergo silencing; silenced alleles become unable to restore
expression after Dox removal. The transition to silencing correlates with
a further reduction in detectable mRNA and hypoacetylation at K9 H3
and is inhibited by TSA treatment (Class I/II HDAC inhibitor). (D)
Additional epigenetic changes (loss of methylation at K4-H3, methyl-
ation at K9-H3, and DNA methylation) occur with continued TG
selection against HPRT expression, as the silenced state stabilizes.
doi:10.1371/journal.pone.0004832.g009
Induced Aberrant Silencing
PLoS ONE | www.plosone.org 8 March 2009 | Volume 4 | Issue 3 | e4832In summary, we used the tet-off system to provide a clear
demonstration that reduced transcriptional potential can sensitize
a promoter to undergo epigenetic silencing. Consistent with prior
work, the results demonstrate that silencing is a multistep process
in which promoter region DNA methylation is secondary to
altered histone modification. We propose that these results are
applicable to tumor suppressor promoters that are repressible by
internal or external environmental exposures and that the model
we created will be useful for identifying molecular determinants of
aberrant silencing in mammalian cells.
Materials and Methods
Tet-Off Constructs
The Tet-Off system has been described previously [24]. The
pTet-Off plasmid (Clontech) expresses the neomycin (Neo)
resistance gene (Neo
r) and tTA, a fusion protein composed of the
amino-terminus of the tetracycline repressor and the activation
domain of the VP16 protein. The 1.38 kb HPRT full-length cDNA
sequence (Accesion # NM_000194.1) was isolated by EcoRI and
XbaI digestion of the TrueClone HPRT cDNA expression vector
(Origene, catalog #TC120047). pTRE-tight-HPRT was created
by directionally cloning the HPRT fragment into the EcoRI and
XbaI restriction sites within the pTRE-Tight (Clontech) multiple
cloning site.
Cell Culture
Dif-6 cells were cultured in Dulbecco’s modified Eagle’s
medium (Hyclone) supplemented with 5% fetal bovine serum
(Hyclone) and 5% Serum Plus (SABC Biosciences). 5610
6 Dif-6
cells were transfected by electroporation [25] with 4 mg of pTet-
Off plasmid (Clontech) that expressed the tTA activating protein
and selected for linked Neo
r with 500 mg/ml of G418. A
transfectant showing high tTA expression was selected for a
second transfection with 10 mgo fPTRE-HPRT and 2 mgo fa
separate plasmid containing a bacterial puromycin (pur) resistance
gene. Stable transfectants expressing functional HPRT were
selected with media containing 10 mg/ml azaserine (Sigma) and
10 mg/ml hypoxanthine (Sigma) (AzHx medium). Selection for the
pur gene was with 1.5 mg/ml puromycin (Invitrogen). Individual
clones were expanded and screened for physical linkage between
pur and PTRE-HPRT by identifying clones with low frequency
PTRE-HPRT inactivation (via TG selection) while retaining
resistance to puromycin. Comparing the PTRE promoter signal
to the Gapdh promoter signal from genomic DNA samples by
quantitative-PCR measured PTRE-HPRT copy number in the cell
lines. HP11 and HP14 contained single copies and HP13
contained two copies of PTRE-HPRT. These parental cells were
routinely cultured in AzHx, G418, and puromycin to retain
expression all constructs and expression of PTRE-HPRT. Doxycy-
cline hyclate (Dox) (Sigma) was added to DMEM at a
concentration of 1 mg/ml for silencing experiments. Dox medium
also contained G418 and puromycin to retain the tTA and PTRE-
HPRT constructs, respectively. These drugs were also used during
TG selection to retain both constructs in clones with silenced
alleles. Cell exposed to Dox were not exposed to AzHx, unless
indicated.
RNA Preparation and Analysis
Total RNA was isolated from cell cultures with the RNeasy
Mini Kit (Qiagen) according to manufacturer’s instructions. Total
RNA samples were converted to cDNA using Quantitect Reverse
Transcription Kit (Qiagen) with removal of genomic DNA
contamination. 100 ng cDNA was used as input in subsequent
quantitative-PCR analysis for either HPRT (TaqMan assay
Hs99999909_m1, Applied Biosystems) or Gapdh (Mouse TaqMan
Endogenous Control, Applied Biosystems) with iQ Supermix (Bio-
Rad) and a Bio-Rad iCycler. HPRT Results were normalized in
relation to Gapdh mRNA levels and displayed relative to an
arbitrary value.
Silencing and Reactivation Cell Cloning Assays
To measure PTRE-HPRT inactivation or reactivation, cells were
plated into 100 mm plates at densities ranging from 1610
4 to
1610
5 cells per plate. The next day the medium was removed,
cells were rinsed with DMEM, and TG or AzHx selective medium
was to select against or for HPRT expression, respectively. Cells
were cultured for approximately two weeks in the appropriate
selective media before staining live colonies with crystal violet
solution. To estimate cloning efficiencies, additional cells were
plated under identical conditions as selective plates but at lower
densities, 250 to 1000 cells per plate and without selection for or
against HPRT expression. Silencing or reactivation frequencies
were calculated by dividing the number of clones growing under
selection by the effective number of cells plated (as determined
with the cloning efficiency plates).
Drug Treatments
Cells were treated with media containing 100 nM TSA (Wako)
overnight (,16 hours) to inhibit histone deacetylation. Cells were
treated with media containing 300 nM 5-aza-dC (Sigma) over-
night (,16 hours) to inhibit DNA methylation. For HPRT mRNA
analysis, cells were allow to recover 24 hours in DMEM after drug
treatment (TSA or 5-aza-dC) before harvesting for RNA
purification.
DNA Methylation Bisulfite Sequencing Assay
Genomic DNA was isolated from cell cultures using DNAzol
(Molecular Research Center) according to the manufacturer’s
instructions. For each treatment, 4 mg of genomic DNA was
digested with Bsr I, and modified in a solution of 6.24 M urea,
4 M sodium bisulfite, and 10 mM hydroquinone as described
previously [4]. PCR amplification of modified DNA, cloning of
PCR products, and sequence analysis were also described
elsewhere [42], with the following exceptions. The primers used
in the initial PCR reaction were the TRE-NaBis-S sense primer
59-GTA TTT ATT AGG GTT ATT GTT TTA TGA G-39 and
the HPRT NaBis-A antisense primer 59-CAA AAT AAA TCA
AAA TCA TAA CCT AAT TC-39.1ml of the PCR product was
used as input in the subsequent semi-nested PCR reaction using
the TRE-NaBis-NS primer 59-GTA TTT AGA AAA ATA AAT
AAA TAG GGG TTT-39 and HPRT-NaBis-A for amplification.
PCR products were cloned using Strataclone PCR cloning kit
(Stratagene). Sequencing analysis showed all cytosine bases not
present in the CpG dinucleotide context were converted to
thymine indicating complete bisulfite modification of the genomic
template occurred.
Chromatin Immunoprecipitation
ChIP assays were carried out using EZ ChIP chromatin
immunoprecipitation kit (Millipore) with the following specific
details or modifications. Proteins were cross-linked to DNA in
5610
7 cells by adding formaldehyde to a final concentration of 1%
and incubating for 10 minutes at room temperature. The cross-
linking reaction was stopped by addition of glycine to a final
concentration of 125 mM and incubating for 5 minutes at room
temperature. Cells were rinsed with cold PBS containing complete
Induced Aberrant Silencing
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buffer. Lysates were sonicated using a Branson 450 microtip
sonicator to shear DNA into 100–1000 bp fragments. Protein-
DNA complexes were immunoprecipitated using antibodies to
acetyl-K9/K14 H3 (06-599, Millipore), acetyl-K9 H3 (07-352,
Millipore), mono/di/trimethyl-K4 H3 (05-791, Millipore), and
dimethyl-K9 H3 (ab1220, Abcam). 5 ml of each specific antibody
was added to lysates from ,1610
6 cells and incubated overnight
at 4uC. Immunocomplexes were isolated by incubating for 3 hours
at 4uC with a 3:1 mixture of Protein A and Protein G conjugated
magnetic Dynabeads (Invitrogen) that had been blocked with
salmonspermDNAand BSA.Beadswerewashedoncewith eachof
the following: low salt buffer, high salt buffer, LiCl buffer, and 16
TE. Immunocomplexes were eluted by incubating beads at 65uC
for 15 minutes in 200 ml elution buffer (50 mM Tris-HCl, 10 mM
EDTA,1%SDS), andthecross-links werereversed by incubatingat
65uC overnight. After incubation with 0.2 mg/ml RNase A at 37uC
for 2 hours and 0.2 mg/ml Proteinase K at 55uC for 2 hours, DNA
was purified using QiaQuick PCR purification kit (Qiagen).
Quantitative PCR using an Icycler and iQ SYBR Green Super-
mix(Bio-Rad) was used to analyze the immunoprecipitated DNA.
The PTRE-HPRT promoter was amplified using the 59-AAC GTA
TGT CGA GGT AGG CGT GTA-39 sense promoter and the 59-
ATC TCC TTC ATC ACA TCT CGA G-39 antisense promoter.
The active Gapdh promoter was amplified using the 59-TTG AGC
TAG GAC TGG ATA AGC AGG-39 sense promoter and the 59-
AAG AAG ATG CGG CCG TCT CTG GAA-39 antisense
promoter.ThesilencedMage-apromoter was amplifiedusingthe 59-
GTTCTAGTGTCCATATTGGTG-39sensepromoterandthe
59-AAC TGG CAC AGC ATG GAG AC-39 antisense promoter.
The specific signal from each immunoprecipitation relative to signal
from input was calculated for the three promoters, PTRE-HPRT,
Gapdh, and Mage. For activating modifications, levels at PTRE-HPRT
are displayed relative to the Gapdh promoter; for the repressive
modification, dimethyl-K9 H3, results are displayed relative to the
Mage promoter.
Supporting Information
Figure S1 Dox treated cells remain sensitive to HPRT selection.
Growth curves of the HP13 (red) and HP14 (blue) cells that had
been treated with Dox for one week to reduce HPRT expression
and allow for protein turnover. After a week, the cells were
maintained in Dox in the presence (dashed lines) or absence (solid
lines) of 5 mg/ml TG (solid lines).
Found at: doi:10.1371/journal.pone.0004832.s001 (0.10 MB TIF)
Figure S2 PTRE-HPRT inactivation correlates with increased
promoter DNA methylation. Expanded allelic methylation
patterns for parental HP14 cells expressing high levels of HPRT
(Untreated), reduced levels of HPRT after a 1 week Dox treatment
(Dox), and HP14-derived TG-resistant clones (TG1–TG6).
Bisulfite sequencing identified methylated (closed triangles) and
unmethylated (open triangles) CpG sites within individual alleles.
Schematic of the promoter shows approximate positioning of CpG
sites (vertical bars) within the minimal CMV promoter (green
shaded box) and the 59 region (,112 bp) of the HPRT cDNA
sequence (grey shaded box). The start of the HPRT cDNA
sequence, EcoR I restriction site (red vertical bar), has been
designated base position +1. The HPRT start codon is marked by
the orange vertical bar.
Found at: doi:10.1371/journal.pone.0004832.s002 (3.99 MB TIF)
Figure S3 Silenced PTRE-HPRT alleles are reactivated by
inhibiting histone deacetylation or DNA methylation. (A) Inhibi-
tion of DNA methylation and histone deacetylation increased
HPRT mRNA levels. HP14-derived TG-resistant cell lines (TG3
and TG4) were treated with 300 nM 5-aza-dC (Aza-dC),
inhibiting histone deacetylation with 100 nM trichostatin A
(TSA), or a combination of the 300 nM 5-aza-dC and 100 nM
TSA treatments (Aza-dC+TSA). Cells were treated with inhibitors
overnight (,16 hours), and RNA was harvested 24 hours later.
The units shown along the Y-axis are relative to those measured in
the untreated parental HP14 cells (see Figure 3). HPRT expression
was measured by qRT-PCR and normalized to Gapdh expression
levels. Each bar represents the average of duplicate reactions with
error bars indicating minimum and maximum fold change. (B)
TG-resistant cell lines were capable of stably reactivating PTRE-
HPRT expression as shown by reversion assay. Cells were plated
with azaserine/hypoxanthine (AzHx) selection, which requires
HPRT enzyme activity for cell survival, to isolate and measure the
number of cells that stably reactivated HPRT expression. Before
plating and selection, cells were treated overnight with 300 nM 5-
aza-dC (Aza-dC), 100 nM TSA (TSA), both 300 nM 5-aza-dC
and 100 nM TSA (Aza-dC+TSA), or vehicle control (Untreated)
and allowed to recover for 24 hours. Frequencies represent the
fraction of cell colonies surviving after two weeks of continuous
AzHx selection.
Found at: doi:10.1371/journal.pone.0004832.s003 (0.26 MB TIF)
Figure S4 Reactivant cell lines have increased HPRT expression
levels. HPRT mRNA levels were measured in reactivant cell lines
(Reactivants A, B, C, and D) and displayed relative to the
expression level in the initial HP13 parental cell line (Untreated).
Also shown for comparison are HPRT expression levels in the
TG-resistant cell line before reactivation (TG), and the parental
line after treatment with Dox for one week (Dox). HPRT
expression was measured by qRT-PCR and normalized to Gapdh
expression levels. Each bar represents the average of duplicate
reactions with error bars indicating minimum and maximum fold
change.
Found at: doi:10.1371/journal.pone.0004832.s004 (0.18 MB TIF)
Acknowledgments
We thank Dr. Phil Yates for a critical reading of this manuscript and Kelly
Sandfort for providing some results.
Author Contributions
Conceived and designed the experiments: JAO MST. Performed the
experiments: JAO AC SB. Analyzed the data: JAO AC SB MST. Wrote
the paper: JAO MST.
References
1. Sawan C, Vaissie `re T, Murr R, Herceg Z (2008) Epigenetic drivers and genetic
passengers on the road to cancer. Mutat Res 642: 1–13. doi:10.1016/
j.mrfmmm.2008.03.002.
2. Esteller M (2008) Epigenetics in cancer. N Engl J Med 358: 1148–59.
doi:10.1056/NEJMra072067.
3. Turker MS (2002) Gene silencing in mammalian cells and the spread of DNA
methylation. Oncogene 21: 5388–93. doi:12154401.
4. Yates PA, Burman R, Simpson J, Ponomoreva ON, Thayer MJ, et al. (2003)
Silencing of mouse Aprt is a gradual process in differentiated cells. Mol Cell Biol
23: 4461–70.
5. Mund C, Brueckner B, Lyko F (2006) Reactivation of epigenetically silenced
genes by DNA methyltransferase inhibitors: basic concepts and clinical
applications. Epigenetics : official journal of the DNA Methylation Society 1:
7–13.
Induced Aberrant Silencing
PLoS ONE | www.plosone.org 10 March 2009 | Volume 4 | Issue 3 | e48326. Gronbaek K, Hother C, Jones PA (2007) Epigenetic changes in cancer. APMIS
115: 1039–59. doi:10.1111/j.1600-0463.2007.apm_636.xml.x.
7. Reik W (2007) Stability and flexibility of epigenetic gene regulation in
mammalian development. Nature 447: 425–32. doi:10.1038/nature05918.
8. Erwin JA, Lee JT (2008) New twists in X-chromosome inactivation. Curr Opin
Cell Biol 20: 349–55. doi:10.1016/j.ceb.2008.04.007.
9. Siegfried Z, Eden S, Mendelsohn M, Feng X, Tsuberi BZ, et al. (1999) DNA
methylation represses transcription in vivo. Nat Genet 22: 203–6. doi:10.1038/
9727.
10. Mutskov V, Felsenfeld G (2004) Silencing of transgene transcription precedes
methylation of promoter DNA and histone H3 lysine 9. EMBO J 23: 138–49.
doi:10.1038/sj.emboj.7600013.
11. Strunnikova M, Schagdarsurengin U, Kehlen A, Garbe JC, Stampfer MR, et al.
(2005) Chromatin inactivation precedes de novo DNA methylation during the
progressive epigenetic silencing of the RASSF1A promoter. Mol Cell Biol 25:
3923–33. doi:10.1128/MCB.25.10.3923-3933.2005.
12. Banelli B, Casciano I, Romani M (2000) Methylation-independent silencing of
the p73 gene in neuroblastoma. Oncogene 19: 4553–6. doi:10.1038/
sj.onc.1203807.
13. Markus J, Garin MT, Bies J, Galili N, Raza A, et al. (2007) Methylation-
independent silencing of the tumor suppressor INK4b (p15) by CBFbeta-
SMMHC in acute myelogenous leukemia with inv(16). Cancer Res 67:
992–1000. doi:10.1158/0008-5472.CAN-06-2964.
14. Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, et al. (2008) Gene
silencing in cancer by histone H3 lysine 27 trimethylation independent of
promoter DNA methylation. Nat Genet 40: 741–50. doi:10.1038/ng.159.
15. Caslini C, Capo-chichi CD, Roland IH, Nicolas E, Yeung AT, et al. (2006)
Histone modifications silence the GATA transcription factor genes in ovarian
cancer. Oncogene 25: 5446–61. doi:10.1038/sj.onc.1209533.
16. Leu Y, Yan PS, Fan M, Jin VX, Liu JC, et al. (2004) Loss of estrogen receptor
signaling triggers epigenetic silencing of downstream targets in breast cancer.
Cancer Res 64: 8184–92. doi:10.1158/0008-5472.CAN-04-2045.
17. Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, et al. (2007)
Downregulation of death-associated protein kinase 1 (DAPK1) in chronic
lymphocytic leukemia. Cell 129: 879–90. doi:10.1016/j.cell.2007.03.043.
18. Krishnamachary B, Zagzag D, Nagasawa H, Rainey K, Okuyama H, et al.
(2006) Hypoxia-inducible factor-1-dependent repression of E-cadherin in von
Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3,
ZFHX1A, and ZFHX1B. Cancer Res 66: 2725–31. doi:10.1158/0008-
5472.CAN-05-3719.
19. Bindra RS, Gibson SL, Meng A, Westermark U, Jasin M, et al. (2005) Hypoxia-
induced down-regulation of BRCA1 expression by E2Fs. Cancer Res 65:
11597–604. doi:10.1158/0008-5472.CAN-05-2119.
20. Bindra RS, Crosby ME, Glazer PM (2007) Regulation of DNA repair in hypoxic
cancer cells. Cancer Metastasis Rev 26: 249–60. doi:10.1007/s10555-007-9061-
3.
21. Lee S, Kim J, Kim W, Lee Y (2008) Hypoxic silencing of tumor suppressor
RUNX3 by histone modification in gastric cancer cells. Oncogene; Available:
http://www.nature.com/onc/journal/vaop/ncurrent/abs/onc2008377a.html.
22. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue KI, et al. (2002) Causal
relationship between the loss of RUNX3 expression and gastric cancer. Cell 109:
113–24. doi:11955451.
23. Li Q, Kim H, Kim W, Choi J, Lee YH, et al. (2004) Transcriptional silencing of
the RUNX3 gene by CpG hypermethylation is associated with lung cancer.
Biochem Biophys Res Commun 314: 223–8. doi:14715269.
24. Gossen M, Bujard H (1992) Tight control of gene expression in mammalian cells
by tetracycline-responsive promoters. Proc Natl Acad Sci U S A 89: 5547–51.
doi:PMC49329.
25. Turker MS, Mummaneni P, Bishop PL (1991) Region- and cell type-specific de
novo DNA methylation in cultured mammalian cells. Somat Cell Mol Genet 17:
151–7. doi:2011793.
26. Dodge JE, Kang Y, Beppu H, Lei H, Li E (2004) Histone H3-K9
methyltransferase ESET is essential for early development. Mol Cell Biol 24:
2478–86.
27. Tachibana M, Ueda J, Fukuda M, Takeda N, Ohta T, et al. (2005) Histone
methyltransferases G9a and GLP form heteromeric complexes and are both
crucial for methylation of euchromatin at H3-K9. Genes Dev 19: 815–26.
doi:10.1101/gad.1284005.
28. Yan C, Boyd DD (2006) Histone H3 acetylation and H3 K4 methylation define
distinct chromatin regions permissive for transgene expression. Mol Cell Biol 26:
6357–71. doi:PMC1592829.
29. McGarvey KM, Fahrner JA, Greene E, Martens J, Jenuwein T, et al. (2006)
Silenced tumor suppressor genes reactivated by DNA demethylation do not
return to a fully euchromatic chromatin state. Cancer Res 66: 3541–9.
doi:10.1158/0008-5472.CAN-05-2481.
30. Egger G, Aparicio A, Escobar S, Jones P (2007) Inhibition of Histone
Deacetylation Does Not Block Resilencing of p16 after 5-Aza-29-Deoxycytidine
\ldots. Cancer Res; Available: http://cancerres.aacrjournals.org/cgi/content/
abstract/67/1/346.
31. Shin-Darlak CY, Skinner AM, Turker MS (2005) A role for Pms2 in the
prevention of tandem CCRTT substitutions induced by ultraviolet radiation
and oxidative stress. DNA Repair (Amst) 4: 51–7. Available: http://www.ncbi.
nlm.nih.gov/pubmed/15533837. Accessed 11 Feb 2009.
32. Hall DB, Struhl K (2002) The VP16 activation domain interacts with multiple
transcriptional components as determined by protein-protein cross-linking in
vivo. J Biol Chem 277: 46043–50. doi:10.1074/jbc.M208911200.
33. Stirzaker C, Song JZ, Davidson B, Clark SJ (2004) Transcriptional gene
silencing promotes DNA hypermethylation through a sequential change in
chromatin modifications in cancer cells. Cancer Res 64: 3871–7. doi:10.1158/
0008-5472.CAN-03-3690.
34. Chen H, Yan Y, Davidson TL, Shinkai Y, Costa M (2006) Hypoxic stress
induces dimethylated histone H3 lysine 9 through histone methyltransferase G9a
in mammalian cells. Cancer Res 66: 9009–16. doi:66/18/9009.
35. Chen H, Ke Q, Kluz T, Yan Y, Costa M (2006) Nickel ions increase histone H3
lysine 9 dimethylation and induce transgene silencing. Mol Cell Biol 26:
3728–37. doi:10.1128/MCB.26.10.3728-3737.2006.
36. Lee YW, Klein CB, Kargacin B, Salnikow K, Kitahara J, et al. (1995)
Carcinogenic nickel silences gene expression by chromatin condensation and
DNA methylation: a new model for epigenetic carcinogens. Mol Cell Biol 15:
2547–57.
37. Bachman KE, Park BH, Rhee I, Rajagopalan H, Herman JG, et al. (2003)
Histone modifications and silencing prior to DNA methylation of a tumor
suppressor gene. Cancer Cell 3: 89–95.
38. Fahrner JA, Eguchi S, Herman JG, Baylin SB (2002) Dependence of histone
modifications and gene expression on DNA hypermethylation in cancer. Cancer
Res 62: 7213–8.
39. Cameron EE, Bachman KE, Myo ¨ha ¨nen S, Herman JG, Baylin SB (1999)
Synergy of demethylation and histone deacetylase inhibition in the re-expression
of genes silenced in cancer. Nat Genet 21: 103–7. doi:10.1038/5047.
40. Li F, Papworth M, Minczuk M, Rohde C, Zhang Y, et al. (2007) Chimeric DNA
methyltransferases target DNA methylation to specific DNA sequences and
repress expression of target genes. Nucleic Acids Res 35: 100–12. doi:10.1093/
nar/gkl1035.
41. Schu ¨beler D, Lorincz MC, Cimbora DM, Telling A, Feng YQ, et al. (2000)
Genomic targeting of methylated DNA: influence of methylation on transcrip-
tion, replication, chromatin structure, and histone acetylation. Mol Cell Biol 20:
9103–12.
42. Hoffman AR, Hu JF (2006) Directing DNA methylation to inhibit gene
expression. Cell Mol Neurobiol 26: 425–38. doi:10.1007/s10571-006-9057-5.
43. Yates PA, Burman RW, Mummaneni P, Krussel S, Turker MS (1999) Tandem
B1 Elements Located in a Mouse Methylation Center Provide a Target for de
Novo DNA Methylation. J Biol Chem 274: 36357–36361. doi:10.1074/
jbc.274.51.36357.
Induced Aberrant Silencing
PLoS ONE | www.plosone.org 11 March 2009 | Volume 4 | Issue 3 | e4832